Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/12/2019
SIETES contiene 92850 citas

 
 
<< anterior 21 a 40 de 55 siguiente >>
Presentar resultados
Seleccionar todas
21.
Roden D M. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22. [Ref.ID 68470]
22.
Anónimo. Attention aux bêtabloquants dans l'insuffisance cardiaque. Prescrire 2003;23:755. [Ref.ID 68361]
23. Cita con resumen
Anónimo. Télithromycine, un macrolide de plus à risque d'interactions. Prescrire 2003;23:751-2. [Ref.ID 68356]
24. Cita con resumen
Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120-7. [Ref.ID 65831]
25.
Mehvar R, Brocks DR, Vakily M. Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs. Clin Pharmacokinet 2002;41:533-58. [Ref.ID 62628]
26.
Oudijk MA, Ruskamp J M, Ambachtsheer BE, Ververs TFF, Stoutenbeek P, Visser GHA, Meijboom EJ. Drug treatment of fetal tachycardias. Pediatr Drugs 2002;4:49-63. [Ref.ID 60682]
27.
Anónimo. Disopyramide: interactions avec des macrolides. Prescrire 2001;21:357-8. [Ref.ID 56601]
28. Cita con resumen
Anónimo. Mesoridazine besilate and thioridazine. Warning: prolongation of the QTc interval. WHO Pharmaceuticals Newsletter 2000;3:3-4. [Ref.ID 54658]
29. Cita con resumen
Takada M, Fujita S, Katayama Y, Harano Y, Shibakawa M. The relationship between risk of hypoglycemia and use of cibenzoline and disopyramide. Eur J Clin Pharmacol 2000;56:335-42. [Ref.ID 51897]
30. Cita con resumen
Lip GYH, Kamath S. Adverse reactions of drugs used to treat arrhythmia. Adv Drug React Bull 2000;201:767-70. [Ref.ID 50835]
31.
Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet 2000;38:271-90. [Ref.ID 49676]
32. Cita con resumen
Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000;40:11-30. [Ref.ID 48842]
33.
Dresser GK, Spence JD, Bailey DG. Pharmacockinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57. [Ref.ID 48634]
34. Cita con resumen
Sopher SM, Ward DE. Flecainide. Prescr J 1999;39:222-6. [Ref.ID 48476]
35. Cita con resumen
Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354:1625-33. [Ref.ID 47650]
36.
37.
Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet 1999;36:233-54. [Ref.ID 43939]
38.
Anónimo. Part 3: A review of drug-induced psychiatric effects. Worst Pills Best Pills 1999;5:12. [Ref.ID 43103]
39.
Joglar JA, Page RL. Treatment of cardiac arrythmias during pregnancy: safety considerations. Drug Saf 1999;20:85-94. [Ref.ID 42288]
40.
Anónimo. Il "caso" cisapride. Informazioni sui Farmaci 1998;22:98. [Ref.ID 40650]
Seleccionar todas
 
<< anterior 21 a 40 de 55 siguiente >>